RxDoctor Payments Data

Kala Brewer

Optometrist · Elkin, NCNPI 1699116723

Payments from drug & device makers

$2,348in general payments, 2019–2025

Across 69 payments — averaging $34.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$544
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$315
  • Sun Pharmaceutical Industries Inc.$229
  • Aerie Pharmaceuticals, Inc.$201
  • Tarsus Pharmaceuticals, Inc.$176
  • AbbVie$171
  • plus $713 from 12 others

What the payments were for

  • Food & beverage$2,29798%
  • Gifts$372%
  • Entertainment$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,348 in reported general payments places this provider in the 70th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$89,910
Medicare patients
312
Services billed
3,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner26$47,839
RestasisCyclosporine37$44,005
VyzultaLatanoprostene Bunod14$5,081
Travoprost36$4,521
Latanoprost107$1,309
Dorzolamide-TimololDorzolamide/Timolol/Pf12$1,183
Timolol Maleate55$865
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat48$767
Prednisolone Acetate22$606
Dorzolamide Hcl15$257
Doxycycline Monohydrate24$254
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha24$250
ErythromycinErythromycin Base19$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$176$47,83926 claims
AbbVieRestasis$171$44,00537 claims
Bausch & Lomb Americas Inc.Vyzulta$154$5,08114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Elkin

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →